Lumacaftor in combination with ivacaftor provides clinically important reductions in the rate of pulmonary exacerbations in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation, new ground-breaking research shows. The phase 3 randomised double blind placebo controlled TRAFFIC and TRANSPORT trials of 1108 patients who were homozygous for the Phe508del mutation found the combination ...
Drug combo a “game-changer” for cystic fibrosis
By Nicola Garrett
18 May 2015